

EMA/18982/2023

European Medicines Agency decision P/0016/2023

of 31 January 2023

on the acceptance of a modification of an agreed paediatric investigation plan for evoncabtagene pazurgedleucel (EMEA-002881-PIP01-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0016/2023

of 31 January 2023

on the acceptance of a modification of an agreed paediatric investigation plan for evoncabtagene pazurgedleucel (EMEA-002881-PIP01-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0321/2021 issued on 11 August 2021,

Having regard to the application submitted by CRISPR Therapeutics AG on 7 September 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 December 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for evoncabtagene pazurgedleucel, dispersion for injection, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to CRISPR Therapeutics AG, 14 Baarerstrasse, CH6300 – Zug, Switzerland.

EMA/PDCO/771518/2022
Amsterdam, 16 December 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002881-PIP01-20-M01

Scope of the application

Active substance(s):

Evoncabtagene pazurgedleucel

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of B-lymphoblastic leukaemia/lymphoma

Treatment of mature B cell neoplasms

Pharmaceutical form(s):

Dispersion for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

CRISPR Therapeutics AG

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, CRISPR Therapeutics AG submitted to the European Medicines Agency on 7 September 2022 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0321/2021 issued on 11 August 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 17 October 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee members of Liechtenstein and Norway agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of B-lymphoblastic leukaemia/lymphoma

2.1.1. Indication(s) targeted by the PIP

Treatment of relapsed/refractory B cell acute lymphoblastic leukaemia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Dispersion for infusion

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Open-label, historically controlled trial in two parts to evaluate pharmacokinetics, safety, activity and immunogenicity of evoncabtagene pazurgedleucel in children from birth to less than 18 years of age with relapsed/refractory B cell acute lymphoblastic leukaemia (ALL) or with relapsed/refractory B cell non-Hodgkin lymphoma (NHL)
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

2.2. Condition:

Treatment of mature B-cell neoplasms

2.2.1. Indication(s) targeted by the PIP

Treatment of relapsed/refractory B cell non-Hodgkin lymphoma

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Dispersion for infusion

2.2.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Same as for condition treatment of B-lymphoblastic leukaemia/lymphoma
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.